Women who inject drugs (WWID) are an especially vulnerable group of drug users. This study determined the prevalence of psychiatric comorbidity and intimate partrner violence (IPV), and factors associated with psychiatric comorbidity among WWID recruited from drug treatment services (67%) and harm reduction services in five European regions in Austria, Catalonia, Italy, Poland, and Scotland. Psychiatric comorbidity was assessed among 226 WWID using the Dual Diagnosis Screening Instrument. IPV was assessed using the Composite Abuse Scale and injecting and sexual risk behaviors were assessed using a battery of questionnaires adapted and developed for the study. Eighty-seven percent met criteria for at least one lifetime psychiatric disorder. The most common disorders were depression (76%), panic (54%), and post-traumatic stress (52%). WWID recruited in drug treatment services were almost three times as likely (OR 2.90 95% CI 1.30-6.43; p = 0.007) to meet criteria for a lifetime psychiatric disorder than those recruited from harm reduction services, specifically dysthymia (OR 5.32 95% CI 2.27-12.48; p = 0.000) and post-traumatic stress disorder (OR 1.83 95% CI 1.02-3.27; p = 0.040). WWID who reported sharing needles and syringes were almost three times as likely to meet criteria for lifetime psychiatric comorbidity than those who did not (OR 2.65 95% CI 1.07-6.56). Compared to WWID who had not experienced IPV, victims (70%) were almost two times more likely to meet criteria for post-traumatic stress disorder (OR 1.95 95% CI 1.10-3.48). Psychiatric comorbidity and IPV among WWID are common. Drug treatment and harm reduction services should address psychiatric comorbidity and IPV to improve treatment outcomes.
Introduction
Among drug users, the number of people who inject drugs (PWID) worldwide is estimated at 12.2 million (UNDOC 2015) . Few studies estimated the number of women who inject drugs (WWID) among drug-injecting populations. Recent findings indicate the proportion ranges from 10 to 30% and rising (UNDOC 2014) . PWID show serious comorbidities that impact negatively on health and treatment; with WWID particularly at risk (UNODC 2015) .
The reason behind is that female drug users are vulnerable to a range of problems, including intimate partner violence (IPV), exposure to sexually transmitted and blood-borne infectious diseases, and prostitution (Brook et al. 2000; Gilchrist et al. 2011 Gilchrist et al. , 2012 Gilchrist et al. , 2017 . Is known that the frequency of IPV victimization is consistently higher among female drug users (Daigre et al. 2015; de Dios et al. 2014; El-Bassel et al. 2000; Gilchrist et al. 2011; Wagner et al. 2009 ) than among other groups of women (Hegarty et al. 2004; Pallitto et al. 2013) . There is extensive literature examining the relationship between drug use and IPV. Longitudinal studies have confirmed the bidirectional relationship between drug use and IPV; with substance use increasing the risk of future IPV episodes, and violence increasing the risk of subsequent substance use (Devries et al. 2014; Kilpatrick et al. 1997) . IPV is also associated with mental health problems among female drug users (Mason and O'Rinn 2014) , and a greater risk for IPV is found when the co-occurrence of mental health problems with substance use is present (McPherson et al. 2007 ). In addition, the experience of IPV has been also associated with sexual and blood-borne viruses (specifically hepatitis C virus (HCV) and HIV) and their associated injecting and sexual risk behaviors among samples of WWID (El-Bassel et al. 2005; Li et al. 2014) . Risk behaviors reported by WWID include multiple sex partners, trading sex for money or drugs, unsafe sexual intercourse, and sharing needles and other injecting materials (Brook et al. 2000) -increasing WWID vulnerability to HCV/ HIV infection. Sharing needles possess the greater risk of transmission among PWID.
Research on the effect of psychiatric disorders, such as depression, on sexual and injecting HIV/HCV risk behaviors has received great attention among PWID (Buckingham et al. 2013; Crepaz and Marks 2001) , with evidence suggesting depressive symptoms predict sexual risk behaviors among injecting drug users (Pettes et al. 2015) and injection-related risk such as needle sharing (Hutton et al. 2004; Perdue et al. 2003; Stein et al. 2001) . A recent study found that more severe depressive symptomatology remained independently associated with engaging in unprotected sex (AOR = 1.62, 95% CI 1.18-2.23) and having multiple sexual partners (AOR = 1.54, 95% CI 1.09-2.19) among women (Pettes et al. 2015) . Further, a study involving 343 American opioid dependents, depressive symptoms were associated with an increase unsafe injection drug use practices (Pilowsky et al. 2011) . Research on how these factors predict or relate to psychiatric comorbidity is still uncertain among WWID, pointing at the need for longitudinal studies to investigate such relationships (Pettes et al. 2015; Torrens et al. 2015) .
Research has found that mental health problems are common among WWID including depression and suicide attempts (Anagnostopoulos et al. 2015) , anxiety disorders (Topp et al. 2010) , and post-traumatic stress disorder (PTSD) (El-Bassel et al. 2011; Johnson et al. 2010) . Recently, a longitudinal study among 564 PWID (34% female) found that participants reported higher psychological distress than the general population. In addition, females reported higher psychological distress than males; however, no significant differences remained after controlling for temporal factors (Scott et al. 2016) .
The assessment of comorbidity among out of treatment drug users has been previously highlighted (Hall et al. 2009 ). Being female, being recruited from an out of treatment setting, and the number of substance use disorders are considered risk factors for psychiatric comorbidity, indicating that participants recruited out of treatment had a greater risk of psychiatric comorbidity .
WWID frequently meet structural and systemic barriers that limit access to general health services (Roberts et al. 2010; Sobrino-Vegas et al. 2014) . Although women are less likely to seek treatment for problematic drug use (Tuchman 2010) , specific characteristics of WWID should not be overlooked when addressing and implementing prevention, treatment, and harm reduction programs for WWID (ElBassel and Strathdee 2015; Iversen et al. 2015) .
Further research is needed to understand the complexity and interactions of these risk factors and the presence or onset of psychiatric comorbidity among WWID. Despite what is already known about the association between drug use and psychiatric disorders, no study has examined the prevalence and risk factors for psychiatric comorbidity among this understudied population (WWID), nor compared the prevalence of psychiatric comorbidity between WWID who are receiving or not receiving treatment for their SUD. The current research addresses this gap of knowledge by comparing the prevalence of specific lifetime psychiatric comorbid disorders and factors (including IPV, HIV, hepatitis C, injecting risk behaviors) associated with such disorders among WWID recruited from drug treatment and harm reduction services in five different European regions.
Materials and methods

Design
Secondary analysis of a cross-sectional study (REDUCE project) was conducted. The REDUCE project was a collaborative European project conducted in Austria, Italy, Poland, Scotland, and Spain (Gilchrist et al. 2016) designed to: (a) develop a toolkit to measure HCV transmission knowledge and HCV risk behaviors among WWID; (b) determine the extent of HCV transmission knowledge and HCV risk behaviors among WWID; (c) develop and test an evidence-based group intervention to increase HCV transmission knowledge and reduce HCV risk-taking behaviors among WWID 18 or older who had injected heroin and/or other opiates, cocaine, or amphetamines in the previous 6 months.
Participants and recruitment
During September 2012 to February 2013, an opportunistic sample of 226 women aged 18 or above who had injected heroin and/or other opiates, cocaine, or amphetamines in the previous 6 months was included in the study. Participants were recruited from community drug treatment services (offering opiate substitution therapy, drug treatment, and needle and syringe exchange) in Vienna (Austria), Ascoli Piceno (Italy), Warsaw (Poland), Paisley (Scotland), and Barcelona (Spain); and harm reduction services with low threshold approach where self-injecting is accepted in Warsaw (Poland) and injecting rooms in Barcelona (Spain) (Gilchrist et al. 2016) . According to the main purpose of the original study, we focused on recruiting females from services that targeted PWID-e. g., syringe-exchange programs and harm reduction services, and intended to test how the intervention works in non-residential setting rather than residential ones where much intensive interventions can be offered. Most participants (66.7%) were receiving treatment for their drug use at the time of recruitment. Treatment for drug use may vary by country, but usually focused on monitoring of substance use, medication management, and psychiatric comorbidity by relevant professionals (psychiatrists, psychologists, and social workers). Other drug-use facilities such as harm reduction facilities included needle-and syringe-exchange programs and injecting rooms focusing on minimizing the harm resulting from injecting drugs.
Procedure
Ethical Committee approval was granted by the relevant university or health service in each country before the study began. All participants were provided with written information about the study, which was also explained to them by the researcher, before informed consent was obtained. Study participants were reimbursed with 10 euros or an equivalent gift voucher for their participation in the study with the exception of Italy, which only used gift vouchers, as it is a common policy of the centers where participants were recruited.
Measurements
All participants were interviewed face-to-face by trained researchers. A structured questionnaire collected demographic data on age, living status, education level, employment, health status, main drug of use, and history of imprisonment. Hepatitis C status was reported by participants and confirmed by information in participants' case notes provided by the specific setting at each country with the exception of Scotland, where self-reported status was used with no confirmation from case notes. Where instruments were not available in partner languages, back translations were undertaken by bilingual staff and approved by the original authors.
Psychiatric comorbidity
Participants were screened for lifetime panic, generalized anxiety disorder, social phobia, agoraphobia, post-traumatic stress, depression, and dysthymia disorders using the Dual Diagnosis Screening Instrument (DDSI) (Mestre-Pintó et al. 2014) . The DDSI is a valid screening instrument to detect the most frequent comorbid psychiatric disorders in substance users. It has shown a sensibility and specificity equal or superior to 80% in all the diagnoses assessed. In addition, the duration of the DDSI administration is about 15 min, and lay interviewers can use after short and easy training. All researchers involved in the study were trained to administer the DDSI.
IPV
IPV in the previous 12 months of their current or most recent intimate relationship was assessed using the Composite Abuse Scale (CAS) (Hegarty et al. 1999 ). This instrument measures four dimensions of IPV: severe combined abuse (experiencing severe combined abuse with any of the other dimensions or by itself), emotional abuse (physical abuse in combination with emotional abuse and/or harassment), physical abuse (physical abuse only), and harassment (experiencing emotional abuse and/or harassment alone). Each item requires a response to the frequency of occurrence in the previous 12 months: Bnever^, Bonly once^, Bseveral times^, Bmonthly^, Bweekly^, or Bdaily^. The instrument shows good internal reliability (Hegarty et al. 2005 ). An accepted cut-off score of ≥ 3 was used to indicate any IPV (100% sensitivity and 4.4% specificity), and a cut-off score of ≥ 7 would correctly detect 95.8% of women with no women labeled abused incorrectly.
Injecting and sexual risk behaviors
Lifetime and past 6-month injecting and sexual risk behaviors associated with hepatitis C were assessed based on two instruments: the Hepatitis C-related knowledge, attitudes, and behaviors questionnaire [HCV-KAB] (Cox et al. 2008 ) and the Needle Exchange Surveillance Initiative (NESI) survey (University of the West of Scotland, Health Protection Scotland, Glasgow Caledonian University and the West of Scotland Specialist Virology Centre 2015). Drug use, injecting preparation and administration, and practices related to sexual activities were assessed.
Analysis
Analysis was performed using SPSS. Frequencies, percentages, mean, and standard deviations (SD) were calculated for dichotomous and continuous variables. Differences between psychiatric comorbidity, types of drugs used (opioids or stimulants), recruitment setting (community drug treatment services compared to harm reduction services), and history of IPV were calculated using chi-square and Fisher's exact test for dichotomous variables. Odds ratios (OR) and 95% confidence intervals (95% CI) were calculated. For the secondary analysis hereby presented, sample was grouped in participants recruited from (a) community drug treatment services or (b) harm reduction services due to previous research reporting higher lifetime psychiatric disorders among drug users out of treatment compared to those receiving treatment for the substance use disorder ) and aimed at finding differences among groups. Conditional logistic regression using author's criteria and backward elimination was performed to determine variables associated with lifetime psychiatric comorbidity (Table 3 ). Significant or clinically relevant variables associated with psychiatric comorbidity (Table 2) were included in the adjusted model. Tables 4 and  5 present the association between IPV in the past 12 months and type of IPV and lifetime psychiatric comorbidity among WWID.
Results
Demographics and drug use history
A total of 226 women were included in the analysis. Recruitment setting was confirmed for 210 participants, 66.7% were recruited from community drug treatment services and 33.3% from harm reduction services. Their mean age was 33.45 years (SD 8.73), with a mean age at first injection of 21.44 years (SD 6.24). Over two-thirds most commonly injected opioids (70.4%) including heroin, methadone, or morphine in the past 6 months. Almost 30% percent reported the drug they most commonly injected in the past 6 months was a stimulant drug including cocaine, amphetamine, efedron, MDMA and mephedrone. Over 75% had used needle and syringe-exchange programs.
Demographic characteristics associated to psychiatric comorbidity are shown in Table 2 . Significant differences were found among those recruited from drug treatment and harm reduction services in the age of participants and household, both higher among participants recruited from harm reduction services (p = 0.000; p = 0.001, respectively).
Lifetime psychiatric comorbidity, type of drug use, recruitment setting, and associated risk factors.
The majority of participants screened positive for at least one lifetime psychiatric disorder (87.2%). The most common disorders were depression (75.7%), followed by panic disorder (53.5%) and post-traumatic stress disorder (51.8%) ( Table 1) . Among those injecting opiates, the most common lifetime psychiatric disorders were depression (77.4%), followed by post-traumatic stress disorder (56%). Among people who injected stimulants, depression (71.6%) and panic (49.3%) disorders were the most commonly associated lifetime disorders. However, no significant differences were found in the prevalence of lifetime psychiatric comorbidity by type of drug most commonly injected (opioids versus stimulants). Although a higher proportion of people who inject opiates than stimulants met criteria for any lifetime psychiatric disorder (p = 0.055) and lifetime post-traumatic stress disorder (p = 0.051), respectively, the odds of having a lifetime psychiatric disorder by drug most commonly injected were nonsignificant.
Among those recruited from community drug treatment services compared to those recruited from harm reduction services, the odds of meeting criteria for any lifetime psychiatric disorder were almost three times greater (OR 2.89 95% CI 1.30-6.4; p = 0.007), five times greater for dysthymia ; p = 0.000), and almost two times Participants recruited from harm reduction facilities were more likely to have been homeless (p = 0.035), inject stimulant drugs (p = 0.000), and having shared needles with someone who was hepatitis C positive in the past 6 months (p = 0.019) ( Table 2) .
Almost 60% were hepatitis C positive. No significant differences were found among different hepatitis C status in the prevalence of lifetime psychiatric comorbidity. A significantly greater proportion of WWID recruited from harm reduction services was hepatitis C seropositive than those recruited from community drug treatment services (p = 0.000) ( Table 2) .
Adjusted variables-significant or clinically relevant variables associated with psychiatric comorbidity-include being involved in prostitution, IPV, HCV, recruitment settings (none of them showed significant ties to psychiatric comorbidity), and sharing needles and syringes. Results from conditional logistic regression showed a significant association between sharing needles and syringes and psychiatric comorbidity (OR 2.65; 95% CI 1.07, 6.56). The association between recruitment setting and psychiatric comorbidity was marginally significant (OR 2.41; 95% CI 0.99, 5.85) ( Table 3) . 
IPV
Sixty-one percent were currently in a relationship and 70% reported having experienced IPV victimization in the last 12 months of their current or most recent relationship. The most commonly experienced IPV was severe combined sexual and physical abuse (37.2%). The odds of experiencing post-traumatic stress disorder was almost two times greater for WWID who reported IPV victimization compared to those who did not (OR 1.95 95% CI 1.10-3.48) ( Table 4 ). Significant differences were found for dysthymia and type of IPV experienced (p = 0.025) ( Table 5) . No association between IPV and psychiatric comorbidity was found (OR 1.63; 95% CI 0.68-3.88) ( Table 3) .
Discussion
Lifetime psychiatric comorbidity was common among the study participants, with 87% screening positive for at least one disorder. The most common disorders were depression (76%), panic (54%), and post-traumatic stress (52%). The rates are similar to other studies conducted among female drug users, where 85% of participants screened positive for anxiety disorders (Gilchrist et al. 2007) or depressive symptoms (74%) (Magnus et al. 2013) . Comparing study prevalence rates becomes challenging due to differences in instruments (diagnosis or screening) and timeframes (current or lifetime) used in studies conducted among female drug users. At present, other studies using the DDSI to assess' psychiatric . A recent secondary analysis aiming to longitudinally examine the relationship between depression and sexual HIV risk-taking behaviors among men and women injecting drug users which included 331 women from Vancouver, found a lower presence of depression (60%) (Pettes et al. 2015) compared to our findings. Although most participants in this study were recruited in drug treatment centers, almost one-third came from harm reduction services. WWID recruited in drug treatment facilities were almost three times as likely to meet criteria for a lifetime psychiatric disorder as those recruited from harm reduction services, mainly showing higher prevalence of dysthymia and post-traumatic stress disorders. In a previous study , people who inject drugs recruited in the streets (neither in harm reduction facilities nor in drug treatment centers) showed higher prevalence of psychiatric comorbidity. An explanation could be related to the characteristics of harm reduction services themselves. These facilities show higher accessibility and a lower threshold approach, and is where information about treatment centers is provided; in this sense, these services mean be the first point of contact with the health system, after which the most complex PWID (i.e. with psychiatric comorbidity) can be addressed to drug treatment services.
A significant association was found between sharing needles and syringes and lifetime psychiatric comorbidity. The findings are consistent with some studies where the presence of depressive symptomatology has been significantly associated with injecting risk behaviors (Disney et al. 2006; Mandell et al. 1999; Stein et al. 2001; Stein et al. 2003) and increased vulnerabilities to experience IPV among female drug users (Gilchrist et al. 2012 ). It has been described that depression may decrease women's ability to negotiate safer injection and sex practices, such as sharing needles or negotiate using condoms with regular or non-regular partners (Pettes et al. 2015; Stein et al. 2001) .
Another important finding of this study is the high prevalence of hepatitis C among WWID being consistent with previous literature (Des Jarlais et al. 2012; von Diemen et al. 2010) . Surprisingly, no significant association has been found between depression or other psychiatric disorders and HCV among WWID, although previous studies suggest that depression is common among HCV-infected patients (Yarlott et al. 2017) , and is associated with taking risk behaviors, including risks of contracting HCV (Stein et al. 2001) . Nevertheless, other studies suggest that HCV infection is seen by PWID as unavoidable part of their lifestyles and its prevention does not constitute any priority no matter if they are depressed or not (Rhodes et al. 2004; Sutton and Treloar, 2007) . In addition, previous studies have found a significant association between hepatitis C and IPV victimization among female drug users . Engagement in higher risk sexual and injecting risk behaviors may be due to the influence of the aggressor (REDUCE team 2013), therefore, this should be considered when prescribing hepatitis C treatment options among WWID due to the possibility of re-infection.
Seventy percent of participants had experienced IPV in the last 12 months. IPV victimization was marginally associated with psychiatric comorbidity and IPV victims were at greater risk for post-traumatic stress disorder.
Consistent with findings, evidence suggests that women who have experienced IPV suffer higher levels of several psychiatric disorders than women who have not experienced IPV. Depression, anxiety, and PTSD are strongly and consistently associated with IPV victimization (Pico-Alfonso et al. 2006 ; Psychiatric comorbidity and intimate partner violence among women who inject drugs in Europe: a... Rees et al. 2011; Trevillion et al. 2012) . Recently, research has reported that women exposed to IPV may be more than twice as likely to suffer with depression in comparison as nonabused women (Blasco-Ros et al. 2010; Devries et al. 2013) . Few studies considered the association of IPV and psychiatric comorbidity among WWID, distinguishing by type of IPVexperienced. Although our analysis found only significant differences between types of IPV experienced with one psychiatric disorder, the findings suggest that psychological IPV may be as damaging as physical IPV and also associated to psychiatric comorbidity (Lövestad et al. 2017; Pico-Alfonso et al. 2006) . The importance of each type of IPV and its potential negative impact on psychiatric comorbidity should be considered for WWID entering drug treatment (Pico-Alfonso et al. 2006) .
Despite the high prevalence of psychiatric comorbidity among female drug users, many drug treatment services do not incorporate screening instruments for psychiatric symptoms or disorders into their routine clinical practice , resulting in a lack of response to these symptoms and disorders (Iversen et al. 2015; Weaver et al. 2001) . These findings highlight the need to integrate screening instruments for psychiatric comorbidity in drug treatment and harm reduction services, especially for females, to increase detection, reduce the severity of psychiatric comorbidity, and improve treatment outcomes for both disorders (Mestre-Pintó et al. 2014; Torrens et al. 2015) . To achieve that, screening instruments should be implemented routinely . There remains a debate about the setting and timing of appropriate treatment provision of psychiatric comorbidity among people with substance use disorders (Kelly and Daley, 2013; Torrens et al. 2012) . It is recommended that IPV and injecting and sexual risk behaviors are also assessed and addressed.
As data show some concurrent psychopathological, social, relational, and medical factors associated with injection among WWID, it must seriously be taken into account when planning interventions. The need for a gender-sensitive approach to screen and address psychiatric comorbidity and associated risk factors among WWID becomes crucial. Designing risk-reduction interventions addressed to PWID with psychiatric comorbidity such us depression, must be considered (Stein et al. 2003) . As above, there is evidence describing how IPV and/or psychiatric comorbidity may heighten the risk of sexual and injection-related risk behaviors among PWID (El-Bassel et al. 2011 Iversen et al. 2015; Stein et al. 2001 ); as such, concerns about IPV have been incorporated into some HIV/HCV prevention strategies for WWID (Gilchrist et al. 2016 ) and managing negative mood has been incorporated to IPV and HCV prevention strategies (Gilchrist et al. 2016; Tirado-Muñoz et al. 2015) . To date, there are psychosocial strategies available to reduce injecting and sexual risk behaviors (Gilchrist et al. 2017; REDUCE team 2013) and IPV victimization (Tirado-Muñoz et al. 2015 ) among female drug users. Due to its nature, these interventions are group and evidence-based interventions that may be delivered in both, treatment and non-treatment facilities.
This study has several limitations. Firstly, the study was not originally powered to study differences in psychiatric comorbidity among participants, which may have increased the possibility of type II errors. Secondly, the instrument used in this study to assess psychiatric comorbidity among participants is a screening instrument, which did not allow diagnosis of psychiatric disorders to be determined among participants. Third, the psychosis module of the DDSI was not included in the assessment, which could have affected the results in terms of presence of psychiatric comorbidity among this population. Furthermore, no axis II psychiatric disorders were assessed in the present study, future research should address this gap in order to include all psychiatric disorders. A potential bias could be related to verbal administration of the instruments, as some respondents may feel ashamed to confirm risk behaviors or mental health symptoms. Another limitation is that there were no case notes available to confirm self-reported hepatitis C status from Scottish participants. Due to the fact that there was no way of checking participants' case notes against their self-reported hepatitis C status in Scotland, it is possible that participants in Scotland may have wrongly understood their hepatitis C status. However, it is arguable that irrespective of their true hepatitis C status, that believing themselves to be either HCV positive or negative was as likely to impact on behavior (or not) as their true status. Therefore, it is possible that lack of ability to confirm participant's status in Scotland has had very little impact on the study's results. Finally, the sample is not random, and therefore, findings may not be generalizable to other groups of WWID. Despite this, the findings contribute to the limited evidence on the prevalence and associated factors with psychiatric comorbidity among WWID.
Conclusion
In conclusion, WWID are an especially vulnerable group of drug users showing serious comorbidities that impact negatively on health and treatment. Psychiatric comorbidity and IPV are common findings among WWID. In addition, an association was found between sharing needles and syringes and lifetime psychiatric comorbidity. Drug treatment and harm reduction services should address psychiatric comorbidity to improve treatment outcomes, for both disorders, among this population.
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